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Abstract
Objectives:  to  investigate  the  rate  of  positivity  for  immunoglobulin  M  anti-Toxoplasma  gondii
(Toxo-IgM) in  newborns  with  congenital  toxoplasmosis,  and  the  age  when  these  antibodies
become  negative.
Methods:  patients  with  congenital  toxoplasmosis  who  started  monitoring  in  a  congenital  infec-
tion clinic  between  1998  and  2009  were  included.  Inclusion  criteria  were  routine  maternal  or
neonatal  serological  screening;  diagnostic  conﬁrmation  by  persistence  of  immunoglobulin  G
anti-Toxoplasma  gondii  at  age  ≥  12  months,  and  Toxo-IgM  screening  in  the  neonatal  period.
To  calculate  the  frequency  of  positive  Toxo-IgM,  cases  detected  by  neonatal  screening  were
excluded.  For  the  study  of  the  age  when  Toxo-IgM  results  became  negative,  patients  with  neg-
ative  Toxo-IgM  since  birth  and  those  in  whom  it  was  not  possible  to  identify  the  month  when
the  negative  result  was  achieved  were  excluded.
Results:  among  the  28  patients  identiﬁed  through  maternal  screening,  23  newborns  had  posi-
tive  Toxo-IgM  (82.1%,  95%  CI:  64.7-93.1%).  When  adding  the  37  patients  identiﬁed  by  neonatal
screening,  Toxo-IgM  was  positive  in  the  ﬁrst  month  of  life  in  60  patients,  and  it  was  possible  to
identify  when  the  result  became  negative  in  51  of  them.  In  19.6%  of  patients,  these  antibod-
ies  were  already  negative  at  30  days  of  life;  and  in  54.9%,  at  90  days.  Among  the  65  patients
included  in  the  study,  40  (61.5%)  had  some  clinical  alteration.
Conclusions:  even  with  high  sensitivity  methods,  newborns  with  congenital  toxoplasmosis  can
have  negative  Toxo-IgM  at  birth.  In  those  who  have  these  antibodies,  the  positive  period  may  be
quite  short.  It  is  important  not  to  interrupt  the  monitoring  of  infants  with  suspected  congenital
toxoplasmosis simply  because  they  present  a  negative  Toxo-IgM  result.
© 2014  Sociedade  Brasileira  de  Pediatria.  Published  by  Elsevier  Editora  Ltda.  
 Please cite this article as: Lago EG, Oliveira AP, Bender AL. Presence and duration of anti-Toxoplasma gondii immunoglobulin M in infants
with congenital toxoplasmosis. J Pediatr (Rio J). 2014;90:363--9.
 Institution and study setting: Hospital São Lucas, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Rio Grande do
Sul.
∗ Corresponding author.
E-mail: eglago@pucrs.br, eleonorlago@terra.com.br (E.G. Lago).
0021-7557      ©  2014  Sociedade  Brasileira  de  Pediatria.  Published  by  Elsevier  Editora  Ltda.  
http://dx.doi.org/10.1016/j.jped.2013.12.006
Este é um artigo Open Access sob a licença de CC BY-NC-ND
Este é um artigo Open Access sob a licença de CC BY-NC-ND
364  Lago  EG  et  al.
PALAVRAS-CHAVE
Toxoplasmose
congênita;
Toxoplasma  gondii;
Imunoglobulina  M/uso
diagnóstico;
Testes  sorológicos;
Triagem  neonatal;
Transmissão  vertical
de doenc¸a infecciosa
Presenc¸a  e  durac¸ão  da  imunoglobulina  M  anti-Toxoplasma  gondii  em  lactentes  com
toxoplasmose  congênita
Resumo
Objetivos:  investigar  a  taxa  de  positividade  para  imunoglobulina  M  anti-Toxoplasma  gondii
(Toxo-IgM) em  recém-nascidos  com  toxoplasmose  congênita,  e  a  idade  de  negativac¸ão  desses
anticorpos.
Métodos:  foram  incluídos  pacientes  com  toxoplasmose  congênita  que  iniciaram  acompan-
hamento em  uma  clínica  de  infecc¸ões  congênitas  entre  1998  e  2009.  Os  critérios  de  inclusão
foram  toxoplasmose  congênita  detectada  por  triagem  sorológica  materna  ou  neonatal  de  rotina,
conﬁrmac¸ão  diagnóstica  por  persistência  de  imunoglobulina  G  anti-Toxoplasma  gondii  com  ≥12
meses  e  pesquisa  de  Toxo-IgM  no  período  neonatal.  Para  o  cálculo  da  frequência  de  posi-
tividade  da  Toxo-IgM  foram  excluídos  os  detectados  por  triagem  neonatal.  Para  o  estudo  da
época  de  negativac¸ão  da  Toxo-IgM  foram  excluídos  os  pacientes  com  Toxo-IgM  negativa  desde
o  nascimento  e  aqueles  em  que  não  foi  possível  identiﬁcar  o  mês  da  negativac¸ão.
Resultados: entre  28  pacientes  detectados  por  triagem  materna,  23  recém-nascidos  tiveram
Toxo-IgM positiva  (82,1%,  IC  95%:  64,7-93,1%).  Somando-se  os  37  pacientes  detectados  por
triagem  neonatal,  a  Toxo-IgM  foi  positiva  no  primeiro  mês  de  vida  em  60  pacientes  e  em  51
foi  possível  identiﬁcar  a  época  de  negativac¸ão.  Em  19,6%  dos  pacientes  esses  anticorpos  já
eram  negativos  aos  30  dias  e  em  54,9%  aos  90  dias.  Entre  os  65  pacientes  incluídos  no  estudo,
40  (61,5%)  apresentaram  alguma  alterac¸ão  clínica.
Conclusões:  mesmo  com  métodos  de  alta  sensibilidade,  recém-nascidos  com  toxoplasmose  con-
gênita  podem  ter  Toxo-IgM  negativa  ao  nascer.  Nos  que  apresentam  esses  anticorpos,  o  período
de  positividade  pode  ser  bastante  fugaz.  É  importante  não  interromper  o  monitoramento  dos
lactentes  com  suspeita  de  toxoplasmose  congênita  por  apresentarem  Toxo-IgM  negativa.
©  2014  Sociedade  Brasileira  de  Pediatria.  Publicado  por  Elsevier  Editora  Ltda.  
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uspected  congenital  toxoplasmosis  can  occur  in  several
ituations: a)  clinical  or  laboratory  evidence  of  toxoplas-
osis acquired  by  the  mother  during  pregnancy;  b)  fetal
onographic abnormalities;  c)  clinical  manifestations  in  the
nfant; and  d)  neonatal  screening,  which  consists  of  the  rou-
ine investigation  of  immunoglobulin  (Ig)-M  anti-Toxoplasma
ondii (Toxo-IgM)  in  capillary  blood.  In  any  of  these  situa-
ions, diagnosis  conﬁrmation  requires  a  number  of  clinical
nd laboratory  examinations.1,2
Treatment  of  congenital  toxoplasmosis  is  indicated  even
n subclinical  cases  with  laboratory  diagnosis,  which  con-
ists primarily  of  IgG  anti-T.  gondii  (Toxo-IgG)  and  Toxo-IgM
n serum.  Although  there  are  other  serological  tests  that
an contribute  to  the  diagnosis,  such  as  speciﬁc  IgE  and
gA tests,  and  Western  blot  IgG/IgM  for  mother/child  pairs,
oxo IgG  and  Toxo-IgM  are  the  most  often  used,  and  they  are
requently the  only  tests  available,  especially  in  Brazil.1--6
As  IgM  does  not  cross  the  placental  barrier,  the  pres-
nce of  Toxo-IgM  in  the  newborn  serum  indicates  congenital
nfection. Conversely,  it  is  known  that  newborn  infants
ith congenital  toxoplasmosis  can  have  negative  Toxo-IgM,
lthough the  frequency  of  this  ﬁnding  is  controversial.7--14
nformation  regarding  the  prevalence  of  positive  results  for
oxo-IgM in  the  newborn,  as  well  as  the  age  at  which  it  tends
o become  negative  in  infants  with  congenital  toxoplasmo-
Eis, is  essential  when  conﬁrming  a  suspected  diagnosis.
This  study  aimed  to  demonstrate  the  dynamics  of  Toxo-
gM in  neonates  and  infants  with  conﬁrmed  congenital
oxoplasmosis. First,  this  study  sought  to  investigate  the
w
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mrequency  these  antibodies  are  detected  in  the  newborn;
nd second,  to  determine,  in  cases  with  positive  Toxo-IgM,  at
hat age  these  results  become  negative.  The  possible  asso-
iations between  the  serological  aspects  and  some  clinical
ariables were  also  investigated.
ethods
his  cohort  study  included  children  whose  monitoring
tarted between  January  of  1998  and  December  of  2009  in
he Congenital  Infection  Clinic  of  Hospital  São  Lucas,  Porto
legre, state  of  Rio  Grande  do  Sul,  Brazil.  The  project  was
pproved by  the  Research  Ethics  Committee  of  the  Pontifí-
ia Universidade  Católica  do  Rio  Grande  do  Sul  and  informed
onsent was  obtained  from  all  parents  or  guardians.
Inclusion  criteria  were:  1)  congenital  toxoplasmosis  con-
rmed by  positive  Toxo-IgG≥  12  months  of  age;  2)  suspected
y routine  serological  screening  (maternal  or  neonatal);  and
) Toxo-IgM  test  since  the  ﬁrst  month  of  life.
Exclusion  criteria  were  determined  according  to  the  two
peciﬁc study  objectives.  To  calculate  the  rate  of  Toxo-IgM
ositivity in  the  newborn,  patients  identiﬁed  by  neonatal
creening (which  must  obligatorily  have  positive  Toxo-IgM
esult) were  excluded.  To  demonstrate  the  time  when  Toxo-
gM results  became  negative,  patients  who  never  had  a
ositive Toxo-IgM  result  were  excluded,  as  well  as  those  in
um artigo Open Access sob a licença de CC BY-NC-NDhom it  was  not  possible  to  identify  the  month  when  the
esult became  negative  (as  there  is  a very  large  gap  between
he last  positive  and  the  ﬁrst  negative  test)  (Fig.  1).  The
onth when  Toxo-IgM  became  negative  was  considered  to
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be  that  when  the  ﬁrst  test  was  negative,  provided  that  the
interval to  the  last  positive  test  did  not  exceed  two  months.
The  studied  variables  were  the  time  of  screening,  pres-
ence of  Toxo-IgM  in  the  ﬁrst  month  of  life,  age  when  the
Toxo-IgM became  negative,  gestational  age,  maternal  and
infant treatment,  presence  of  cerebral  calciﬁcations,  and
presence of  retinochoroiditis  within  the  ﬁrst  year  of  life.  Sus-
picion due  to  maternal  screening  occurred  when  pregnant
woman with  negative  tests  showed  seroconversion  or  sero-
logy consistent  with  recent  toxoplasmosis  (positive  Toxo-IgM
and/or low  Toxo-IgG  avidity)  detected  in  the  prenatal  period
or at  the  time  of  hospitalization  for  childbirth.  In  these
cases, serological  tests  in  newborns  were  performed  in
peripheral blood  samples  during  their  stay  in  the  maternity
ward, and  repeated  at  varying  intervals  according  to  clinical
indication.
The start  of  treatment  for  congenital  toxoplasmosis  was
indicated in  the  presence  of  one  or  more  of  the  following
situations: a)  positive  Toxo-IgM  in  the  newborn;  b)  typi-
cal clinical  manifestations  of  congenital  toxoplasmosis;  c)
increased Toxo-IgG  during  the  ﬁrst  months  of  life.
The  method  used  for  Toxo  IgG  and  Toxo-IgM  identiﬁcation
in serum  was  the  enzyme  linked  ﬂuorescent  assay  (ELFA;
BioMérieux -  Marcy  l’Etoile,France),  whose  cutoffs  for  IgM
are index  value  <  0.55  for  negativity  and  >  0.65  for  positivity.
A ﬂuorometric  enzyme  immunoassay  (FEIA;  Ani  LabSystems
- Helsinki,  Finland)  was  used  to  test  Toxo-IgM  on  ﬁlter  paper.
The presence  of  retinochoroiditis  in  newborns  was  assessed
by indirect  ophthalmoscopy,  and  calciﬁcations  were  investi-
gated by  computed  tomography  or  ultrasound.
Data  were  recorded  prospectively  in  medical  records,
entered in  an  Excel  ﬁle  (Microsoft  Corp.  -  USA),  and  analyzed
through Epi  Info  3.5.1  (Centers  for  Disease  Control  and  Pre-
vention -  Atlanta,  United  States).  Absolute  frequencies  and
percentages were  described,  possible  associations  between
variables were  investigated  by  chi-squared  test  or  Fisher’s
exact test,  correlations  were  assessed  using  Pearson’s  cor-
relation, and  comparison  between  medians  were  performed
by the  Mann-Whitney/Wilcoxon  test,  considering  signiﬁcant
a p-value  <  0.05.
Results
Included  patients
Inclusion  criteria  were  met  by  65  patients  among  89  chil-
dren with  congenital  toxoplasmosis  whose  monitoring  at  the
Clinic of  Congenital  Infections  started  during  that  period.
Twenty-four patients  were  not  included;  in  14  the  suspected
diagnosis occurred  at  symptom  onset,  eight  had  no  serology
at 12  months  of  age  or  older,  and  two  patients  that  met  the
initial criteria  lacked  Toxo-IgM  test  in  the  ﬁrst  month  of  life.
Of  the  65  patients  included,  28  were  detected  by  mater-
nal screening  (15  in  the  prenatal  period  and  13  at  delivery)
and 37  by  neonatal  screening.  The  number  of  patients
excluded for  each  study  objective,  according  to  the  criteria
mentioned in  the  methodology,  is  described  below.Clinical  manifestations
Among  the  65  patients  included,  40  (61.5%;  95%  conﬁdence
interval [CI]:  49.3%  to  72.7%)  had  some  clinical  alteration
s
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ithin  the  ﬁrst  year  of  life,  considering  only  retinochoroidi-
is and  cerebral  calciﬁcations  (without  including  other
entral nervous  system  abnormalities,  such  as  ventricular
ilation). Cerebral  calciﬁcations  and  retinochoroiditis  were
etected  in  25  patients  (38.4%),  ten  (15.3%)  had  only  cal-
iﬁcations, four  had  only  retinochoroiditis,  and  one  patient
ad retinochoroiditis  and  did  not  undergo  imaging  examina-
ion; for  statistical  purposes,  this  patient  was  added  to  those
hat had  only  retinochoroiditis,  totaling  ﬁve  cases  (7.7%)
n this  category  (Fig.  1).  Therefore,  cerebral  calciﬁcations
ere seen  in  35  patients  (53.8%;  95%  CI:  41.6%  to  65.6%)  and
etinochoroiditis was  detected  in  30  (46.1%;  95%  CI:  34.3%
o 58.3%)  within  the  ﬁrst  year  of  life.
oxo-IgM  positivity  in  the  neonatal  period
o  calculate  the  prevalence  of  positive  Toxo-IgM  in  the  new-
orn, the  37  patients  identiﬁed  by  neonatal  screening  were
xcluded. Among  the  28  patients  in  whom  clinical  suspicion
rose due  to  maternal  serology,  20  had  positive  Toxo-IgM  on
he ﬁrst  day  of  life,  conﬁrmed  after  over  one  week  (71.4%;
5% CI:  52.8%  to  85.7%),  while  eight  had  negative  Toxo-IgM
n the  ﬁrst  day  (28.6%;  95%  CI:  14.2%  too  47.1%).  In  three
f these,  Toxo-IgM  became  positive  after  the  second  week,
nd Toxo-IgG  became  positive  shortly  after.  The  mothers  of
hese patients  had  evidence  of  T.  gondii  infection  that  had
ccurred a  few  days  before  delivery.  Therefore,  of  the  28
atients, ﬁve  never  had  positive  Toxo-IgM  (17.9%;  95%  CI:
.8% to  35.2%),  whereas  23  had  positive  Toxo-IgM  in  the
eonatal period  (82.1%;  95%  CI:  64.7%  to  93.1%)  (Fig.  1).
n this  study,  no  cases  of  false  Toxo-IgM  positivity  were  iden-
iﬁed.
ime  when  Toxo-IgM  results  became  negative
he  23  patients  detected  by  maternal  serological  tests  that
howed positive  Toxo-IgM  (after  excluding  the  ﬁve  who  never
ested positive),  in  addition  to  the  37  detected  by  newborn
creening, comprise  the  60  newborns  with  positive  Toxo-IgM
n the  ﬁrst  month  of  life.  To  study  the  time  when  Toxo-IgM
esults became  negative,  nine  patients  for  whom  the  month
hen results  became  negative  could  not  be  identiﬁed  had  to
e excluded,  since  the  interval  between  the  ﬁrst  negative
nd the  last  positive  test  was  >  two  months  (Fig.  1).  Thus,
t was  possible  to  demonstrate  the  month  in  which  Toxo-IgM
ecame negative  in  51  patients  (Table  1).
reatment  of  the  mother
one  of  the  mothers  of  the  patients  identiﬁed  through
aternal screening  at  delivery  or  neonatal  screening  had
eceived treatment  for  toxoplasmosis.  Among  the  15  moth-
rs whose  toxoplasmosis  was  diagnosed  in  the  prenatal
eriod, 12  had  received  some  type  of  treatment  before
elivery. Considering  all  28  patients  detected  by  maternal
creening, it  was  observed  that  among  the  12  mothers  who
eceived treatment,  three  newborns  (25%)  had  never  had
ositive Toxo-IgM,  whereas  of  the  16  mothers  who  did  not
eceive treatment,  two  newborns  (12%)  showed  the  same
366  Lago  EG  et  al.
89 children with congenital toxoplasmosis were followed-up
In 51 it was possible to identify the month when 
results became negative
Included in the study:b time when Toxo-IgM
showed negative results
(Table 1)
It was not possible to 
identify the month 
when results became 
negative = nine
28 identified by maternal screening
(15 in the prenatal and 13 at delivery)
Included in the study:a prevalence of 
positive Toxo-IgM in the newborns
37 identified by neonatal screening
(positive Toxo-IgM)
60 with positive
Toxo-IgM 
23/28 (82.1%) with
positive
Toxo-IgM 
5/28 (17.9%) 
with
negative 
Toxo-IgM 
Suspected after symptom onset = 14
No positive serology at age ≥ 12 months =   
eight
Identified by screening but no Toxo-IgM test 
in the first month of life = two
65 met the inclusion criteria:
- Congenital toxoplasmosis confirmed by positive Toxo-IgG at age ≥ 12 months
- Suspected at routine serological screening (maternal or neonatal)
- Toxo-IgM test since the first month of life
40/65 (61.5%) with some clinical manifestation
(considering only retinochoroiditis and cerebral calcifications )
Ten (15.4%) with cerebral calcifications only
25 (38.4%) with retinochoroiditis and calcifications
Five (7.7%) with retinochoroiditis only                                30 (46.1%) with retinochoroiditis
35 (53.8%) with calcifications
Figure  1  Distribution  of  inclusion  and  exclusion  criteria  for  the  study.  Patients  who  started  follow-up  between  1998  and  2009  in  the
Congenital  Infection  Outpatient  Clinic  of  Hospital  São  Lucas,  Porto  Alegre,  RS,  Brazil.  Toxo-IgM:  Immunoglobulin  M  anti-Toxoplasma
gondii,  analyzed  by  immunoenzymatic  capture  assay.
a Prevalence  of  positivity  for  immunoglobulin  M  anti-Toxoplasma  gondii  (Toxo-IgM)  in  the  newborn.
b Time  of  the  negative  results  for  Toxo-IgM.
IgM  anti-T.  gondii  in  infants  with  congenital  toxoplasmosis  
Table  1  Age  when  negative  results  were  observed  for
immunoglobulin M  anti-Toxoplasma  gondii  in  51  infants  with
conﬁrmed  congenital  toxoplasmosis  who  showed  a  positive
result for  these  antibodies  in  the  ﬁrst  month  of  life.
Age  at  negative  results
for Toxo-IgM
N (%)  Cumulative
percentage  (%)
15  days  3  (5.9)  5.9
1  month  7  (13.7)  19.6
2  months  11  (21.6)  41.2
3  months 7 (13.7) 54.9
4  months 8 (15.7) 70.6
5  months 5 (9.8) 80.4
6  months  3  (5.9)  86.3
7  months  2  (3.9)  90.2
8  months  3  (5.9)  96.1
10  months 2 (3.9) 100.0
Total 51  (100)
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cToxo-IgM, Immunoglobulin M anti-Toxoplasma gondii tested by
an  immunoenzymatic capture assay.
characteristic  (odds  ratio  [OR]  2.33;  95%  CI:  0.28-  22.25;
p =  0.4).
Treatment  of  the  infant
After  excluding  the  ﬁve  infants  who  never  had  positive  IgM,
treatment start  was  earlier  in  those  whose  identiﬁcation  was
through maternal  screening  than  in  those  who  were  identi-
ﬁed by  neonatal  screening.  In  the  ﬁrst,  the  median  age  at
start of  treatment  was  5.5  days  (interquartile  range:  4-23;
minimum 1,  maximum  52),  whereas  in  the  latter  the  median
was 45  days  (interquartile  range:  31-62;  minimum  17,  max
275; p  =  0.0003).  However,  when  comparing  the  groups  iden-
tiﬁed through  maternal  or  neonatal  screening  in  relation
to the  time  when  Toxo-IgM  became  negative,  there  was  no
signiﬁcant difference.
In  those  with  suspected  diagnosis  at  the  maternal
screening, median  age  of  negative  result  was  3  months
(interquartile range:  2-6,  minimum  1,  maximum  10),
whereas in  those  detected  by  neonatal  screening,  the
median age  was  4  months  (interquartile  range:  2--6;  mini-
mum 0,  maximum  10;  p  =  0.3752).
Considering  all  51  infants  in  whom  it  was  possible  to
identify the  time  when  Toxo-IgM  became  negative,  linear
regression showed  no  correlation  between  age  in  days  at
start of  treatment  and  the  age  at  the  negative  result  (Pear-
son’s correlation  coefﬁcient  =  0.03).
In one  of  the  ﬁve  patients  that  never  had  positive  IgM,
treatment was  started  on  the  second  day  of  life,  but  in  four
of them  the  start  occurred  later  (between  1  and  4  months).
In six  of  the  patients  whose  negative  Toxo-IgM  results
occurred within  1  month  of  age,  the  only  positive  sample
was the  one  collected  at  the  routine  neonatal  screening.
These mothers  and  their  newborns  had  not  received  any
treatment for  toxoplasmosis.  In  four  cases,  who  were  asymp-
tomatic at  the  ﬁrst  clinical  evaluation,  as  well  as  in  two
other patients  (part  of  the  ﬁve  who  had  never  had  a  posi-
tive Toxo-IgM  result),  treatment  was  started  based  on  the
Toxo-IgG increase  after  the  third  month  of  life.
o
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ther  variables
here  was  no  association  of  other  variables  (presence  of  clin-
cal manifestations  and  gestational  age)  with  the  positivity
r negativity  of  Toxo-IgM  at  birth  or  age  when  the  results
ecame negative.
iscussion
n  addition  to  assessing  the  positivity  rate  of  Toxo-IgM  in
ewborns with  conﬁrmed  congenital  toxoplasmosis,  this
tudy demonstrate,  for  the  ﬁrst  time  by  means  of  a  cohort
esign, the  age  at  which  these  antibodies,  when  present  in
he neonatal  period,  become  negative,  which  often  occurred
arly. This  information  is  important  for  the  proper  manage-
ent of  cases  of  suspected  congenital  toxoplasmosis,  since
he clinical  investigation  must  be  thorough  in  these  infants,
nd monitoring  cannot  be  interrupted,  even  in  the  absence
f Toxo-IgM  in  serum.
Regarding the  proportion  between  positivity  and  negativ-
ty for  Toxo-IgM  in  newborns  with  congenital  toxoplasmosis,
he data  in  the  literature  are  quite  discrepant,  partly
ecause of  the  different  sensitivities  of  the  methods
sed and  partly  due  to  population  characteristics.7--14
o  achieve  accuracy  when  testing  Toxo-IgM,  it  is  neces-
ary to  use  a capture  method,  with  high  sensitivity  and
peciﬁcity.1
In  the  state  of  Goiás,  Rodrigues  et  al.14 evaluated  28
nfants with  congenital  toxoplasmosis  in  relation  to  the
ositivity of  speciﬁc  IgM  antibodies.  Using  two  immunoen-
ymatic capture  methods,  it  was  observed  that  16  (57%;
5% CI:  38%  to  74%)  had  negative  Toxo-IgM.14 A  French  study
bserved that,  of  103  patients  with  congenital  toxoplasmo-
is, 31  (30%;  95%  CI:  21%  to  39%)  had  negative  Toxo-IgM  in
he ﬁrst  month  of  life,  also  performed  by  enzyme  immunoen-
ymatic capture  method.10 The  positivity  rate  found  in  the
resent study  is  among  the  highest  when  compared  to  these
nd other  published  data;7--15 yet,  it  was  evident  that  up  to
ne-third of  the  newborns  with  congenital  toxoplasmosis  in
his population  may  be  negative  for  Toxo-IgM  even  using  a
ighly sensitive  method.16
Factors  that  may  inﬂuence  the  presence  or  absence
f Toxo-IgM  in  the  newborn  include  concentration  of
aternal antibodies  and  treatment  during  pregnancy.  It
as been  demonstrated  that  the  treatment  of  pregnant
omen decreases  the  rate  of  positive  Toxo-IgM  in  the
ewborn.8,17 Although  the  present  study  found  a  2.33-OR
or the  effect  of  maternal  treatment  on  Toxo-IgM  negativity
n the  newborn,  the  conﬁdence  interval  was  not  statis-
ically signiﬁcant,  so  this  effect  cannot  be  ruled  out  or
onﬁrmed in  the  study  population.  Bessières  et  al.12 found
o difference  in  Toxo-IgM  positivity  in  the  newborn  when
omparing two  types  of  maternal  treatment  (spiramycin  or
yrimethamine +  sulfadoxine).
Three  newborns  of  mothers  with  very  recent  infection
ho tested  negative  on  the  day  of  birth  showed  later  sero-
onversion. The  risk  of  infections  going  unnoticed  at  the  end
f gestation  has  been  highlighted  in  the  literature.18 When
aternal infection  is  very  recent,  the  newborn  should  be
etested in  two  weeks,  if  the  serology  performed  at  birth
hows a  negative  result.
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This  cohort  study  conﬁrms  that  the  period  during  which
oxo-IgM remains  positive  in  infants  with  congenital  toxo-
lasmosis is  very  restricted:  over  half  of  infants  with  positive
oxo-IgM in  the  neonatal  period  already  tested  negative  at
hree months  of  age.  Gilbert  et  al.13 and  Olariu  et  al.15 also
emonstrated that  Toxo-IgM  positivity  decreases  with  age;
owever, the  design  of  those  studies  was  cross-sectional,
alculating the  rate  of  negativity  in  infants  by  age  groups,
ithout longitudinal  follow-up.
In  the  present  study,  it  was  observed  that,  in  20%  of
ewborns, Toxo-IgM  was  already  negative  at  1  month  of
ge, when  serum  conﬁrmatory  tests  are  performed  in  most
atients with  positive  Toxo-IgM  at  the  neonatal  screening.
lthough not  included  in  the  national  program,  neona-
al screening  for  congenital  toxoplasmosis  is  a  reality  in
razil, where  most  health  insurance  plans  provide  for  its
erformance.19--21 At  least  six  patients  in  this  cohort  would
e diagnosed  only  after  months  or  years,  after  symptom
nset, if  the  neonatal  screening  test  had  been  considered
 false  positive  due  to  the  early  negative  Toxo--IgM  test,
reventing the  indication  for  full  clinical  investigation,  as
ell as  the  monitoring  of  Toxo-IgG.  Pediatricians  should
e warned  to  not  to  consider  a  negative  Toxo-IgM  result
n infants  as  evidence  of  absence  of  congenital  infection.
hese infants  should  undergo  a  thorough  medical  investiga-
ion; and  when  this  is  normal,  Toxo--IgG  should  be  monitored
onthly until  a  total  negative  result  or  conﬁrmatory  diag-
osis is  attained.
Other tests,  such  as  speciﬁc  IgA  test  (which,  together
ith Toxo-IgM  screening,  moderately  increase  sensitivity)
nd molecular  biology  tests,  can  be  performed  to  attempt
onﬁrmation of  the  diagnosis  as  early  as  possible.1,10,11,15
Although  it  is  well  known  that  treatment  in  infants
ecreases Toxo-IgG  levels,1,2 this  study  indicated  that  the
ame does  not  occur  with  Toxo-IgM  levels.  The  analyses
howed no  inﬂuence  of  the  treatment  on  Toxo-IgM  duration.
Some  clinical  data  were  collected  aiming  to  investigate
heir association  with  the  dynamics  of  Toxo-IgM  in  the  infant.
lthough the  present  study  did  not  aim  to  assess  the  preva-
ence of  clinical  manifestations  in  congenital  toxoplasmosis,
nd subjected  to  the  biases  inherent  to  the  inclusion  criteria
mployed, the  authors  believe  the  fact  that  the  study  did
ot include  patients  with  diagnostic  suspicion  due  to  symp-
om onset  and  used  a  strict  diagnostic  conﬁrmation  criterion
akes this  a  representative  investigation  of  the  studied  pop-
lation by  offering  relevant  information,  provided  that  its
imitations are  taken  into  account.
The  prevalence  of  clinical  manifestations  in  this  sample
f patients  (more  than  60%  with  retinochoroiditis  and/or
erebral calciﬁcations)  appears  to  conﬁrm  the  higher  mor-
idity of  the  infection  in  Brazilian  and  South  American
hildren in  general,  when  compared  to  children  from  other
ontinents, such  as  Europe  and  North  America,  where  clin-
cal manifestations  are  described  at  birth  in  approximately
0% of  infected  newborns.20,22--26
Vasconcelos-Santos  et  al.20 observed  a  higher  prevalence
f retinochoroiditis,  79.8%  (95%  CI:  73.4%  to  85.1%)  in  a  pop-
lation of  infants  with  congenital  toxoplasmosis  detected
y neonatal  screening  in  the  state  of  Minas  Gerais,  Brazil.
n that  study,  ophthalmological  assessment  was  decisive
n 15.7%  of  infants  who  no  longer  showed  positive  Toxo-
gM at  the  conﬁrmatory  serology,  similar  to  the  situation
o
T
aLago  EG  et  al.
bserved  in  the  present  study.20 Melamed  et  al.,27 evaluat-
ng 44  infants  with  congenital  toxoplasmosis,  some  of  whom
elonged to  the  present  cohort,  observed  31  (70.4%)  cases
f eye  lesion,  29  (65.9%)  of  which  were  retinochoroiditis.
ye lesions  may  become  evident  within  the  months  follow-
ng birth,  not  only  due  to  the  appearance  of  new  lesions,  but
lso  due  to  greater  facility  to  visualize  the  peripheral  retina.
ifferences in  clinical  presentation  of  congenital  toxoplas-
osis among  populations  can  be  explained  by  genetic  factors
f the  host  and  parasite.20,28,29 This  reason  adds  importance
o studies  in  different  geographical  areas.
In  the  study  by  Vasconcelos-Santos  et  al.,20 the  preva-
ence of  cerebral  calciﬁcations  was  20.5%;  neuroimaging
tudies included  radiographs  and  ultrasound.  Other  studies
hat also  detected  a  lower  prevalence  of  cerebral  calciﬁ-
ations than  that  of  the  present  study  generally  included
kull radiographs  among  the  neuroimaging  tests,  which  have
nown low  sensitivity  to  detect  calciﬁcations.26,30 In  the
resent study,  neuroimaging  studies  were  performed  by
omputed tomography  and/or  ultrasound,  a  characteris-
ic that  was  taken  into  account  when  including  part  of
his same  cohort  in  comparative  studies  with  European
hildren, demonstrating  that  most  Brazilian  patients  had
ndergone skull  CT,  which  can  increase  the  detection  of
alciﬁcations.15,24,31
This  study  observed  no  association  between  Toxo-
gM positivity  in  the  newborn  and  clinical  manifestations
f congenital  toxoplasmosis,  as  did  studies  by  other
uthors.1,11,13,15 A  higher  prevalence  of  negative  Toxo-IgM
n symptomatic  children  would  be  expected,  as  there  is  a
reater tendency  toward  negativity  in  newborns  in  whom
etal infection  occurred  at  earlier  times  of  gestation,  and
ho tend  to  be  more  severely  affected  and  show  evident
hanges on  physical  examination.
Wallon  et  al.,11 Bessières  et  al.,12 and  Gilbert  et  al.13
emonstrated  that  the  detection  of  Toxo-IgM  in  newborns
as lower  in  cases  of  maternal  seroconversion  that  occurred
n the  ﬁrst  and  second  trimesters  of  gestation.  There  are  two
ossible reasons  for  the  gestational  age  of  maternal  infec-
ion to  inﬂuence  the  presence  of  Toxo-IgM  in  the  newborn:
rst, in  earlier  infection  cases,  the  time  between  placental
nd fetal  infection  is  longer,  allowing  increased  passage  of
aternal antibodies  to  the  fetus  and  inhibiting  fetal  produc-
ion of  these  antibodies.  Second,  the  early  infection  would
llow time  for  fetal  Toxo-IgM  to  have  reached  its  peak  during
ntrauterine life  and  already  be  negative  at  birth.
In  European  studies,  it  is  possible  to  assess  the  moment
f maternal  infection  because  prenatal  routine  assessment
ncludes monthly  serology,  which  does  not  occur  in  Brazil;
hus, the  seroconversion  trimester  usually  cannot  be  exactly
dentiﬁed. This  limitation  can  also  be  found  in  the  United
tates, where  no  routine  prenatal  serology  is  performed.15
It  can  be  concluded  that,  even  when  tested  using  serolog-
cal methods  with  high  sensitivity,  up  to  one-third  of  infants
ith congenital  toxoplasmosis  may  be  negative  for  Toxo-IgM
t birth.  In  cases  of  maternal  infection  that  occurred  very
lose to  the  time  of  delivery,  newborns  can  show  positive
erology for  toxoplasmosis  a few  days  or  weeks  after  birth.  In
ost newborns  or  infants  with  positive  Toxo-IgM,  the  period
f positivity  is  quite  brief.  Infected  children  with  positive
oxo-IgM in  the  neonatal  screening  may  already  be  negative
t the  time  of  conﬁrmatory  testing,  which  should  not  be
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initially  regarded  as  false  positivity  of  the  screening  test.
It is  important  not  to  interrupt  the  monitoring  of  infants
with suspected  congenital  toxoplasmosis  due  to  a  negative
Toxo-IgM result.
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